×
Baxter Receivables 2010-2024 | BAX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Baxter receivables for the quarter ending September 30, 2024 were
$2.639B
, a
5.77% increase
year-over-year.
Baxter receivables for 2023 were
$2.69B
, a
4.63% increase
from 2022.
Baxter receivables for 2022 were
$2.571B
, a
2.21% decline
from 2021.
Baxter receivables for 2021 were
$2.629B
, a
30.99% increase
from 2020.
View More
Baxter Receivables 2010-2024 | BAX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Baxter receivables for 2023 were
$2.69B
, a
4.63% increase
from 2022.
Baxter receivables for 2022 were
$2.571B
, a
2.21% decline
from 2021.
Baxter receivables for 2021 were
$2.629B
, a
30.99% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$202.2B
Stryker (SYK)
$143.3B
Boston Scientific (BSX)
$130.1B
Medtronic (MDT)
$112.5B
EssilorLuxottica (ESLOY)
$111.7B
Lonza Group Ag (LZAGY)
$45.4B
Haleon (HLN)
$43.5B
GE HealthCare Technologies (GEHC)
$39.3B
ResMed (RMD)
$37B
Terumo (TRUMY)
$29.6B
Koninklijke Philips (PHG)
$25B
Zimmer Biomet Holdings (ZBH)
$21.5B
Insulet (PODD)
$18.8B
Smith & Nephew SNATS (SNN)
$10.6B
Bio-Rad Laboratories (BIO)
$10.3B
BellRing Brands (BRBR)
$9.1B
Demant (WILYY)
$8.4B
Lantheus Holdings (LNTH)
$6.1B
Haemonetics (HAE)
$4.5B
TG Therapeutics (TGTX)
$4.5B
ICU Medical (ICUI)
$4.3B
Prestige Consumer Healthcare (PBH)
$4B
Perrigo (PRGO)
$3.6B
Neogen (NEOG)
$3.5B
Envista Holdings (NVST)
$3.5B
Agios Pharmaceuticals (AGIO)
$3.4B
GN Store Nord (GNNDY)
$3B
Shandong Weigao Medical Polymer (SHWGF)
$3B
QuidelOrtho (QDEL)
$2.9B
LeMaitre Vascular (LMAT)
$2.3B